Alk-Abello A/S, of Horsholm, Denmark, presented positive trial results on its new sublingual allergy immunotherapy tablet (SLIT-tablet) for house dust mite (HDM) respiratory allergic diseases at the 2014 Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Copenhagen. The medicine works by addressing the underlying causes of HDM respiratory allergic diseases. It is the first allergy immunotherapy product with a comprehensive clinical development program aimed at treating both upper and lower airway manifestations of HDM-induced allergic respiratory diseases (namely allergic rhinitis and allergic asthma, respectively), Alk said. Two trials involved more than 1,800 patients. The trials form part of the largest clinical development program in the history of allergy immunotherapy, involving more than 5,000 patients from Europe, North America and Japan, according to Alk.